Telik Inc.
About Telik Inc.
Telik, Inc. (Nasdaq: TELK) of Palo Alto, CA is a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases.
The Company discovered all of its product candidates using its proprietary technology, Target-Related Affinity Profiling (TRAP).
Their most advanced product is TELCYTA™ (TLK286), a novel cancer cell-activated chemotherapeutic currently in three Phase 3 registration trials in advanced ovarian cancer and non-small cell lung cancer. A second development candidate, TELINTRA™ (TLK199), is in a Phase 2 clinical trial in myelodysplastic syndrome and may also have utility in the treatment of chemotherapy-induced cytopenia.
TELCYTA --advanced ovarian cancer and non-small cell lung cancer
TELINTRA myelodysplastic syndrome
More About Telik